Equine Amnio Solutions

Renovo Equine shares news and announcements about new products, research, and events.

Why RenoVō uses cryopreservation to protect the biological integrity of equine amniotic allograft, and how it differs from lyophilization.

The page compares RenoVō, an acellular, ready-to-use amniotic allograft, with Alpha2EQ, an autologous A2M concentrate, for equine use.

A side by side comparison of PRP and RenoVō for equine regenerative therapy, covering composition, preparation and clinical consistency.

RenoVō is a ready-to-use alternative to PRP for equine regenerative care and requires no chairside preparation.

Meet Ann Kolesar, MBA, Senior Director at Equus Innovations, leading quality for RenoVō equine solutions in regenerative medicine and horse arthritis treatments.

Christian Beaudry, MBA, brings 25 years in biopharmaceuticals. As COO at Equus Innovations he leads R and D for RenoVō and AlphaFlo biologics.

Meet Dr. Ginger Johnson, DC, DACNB, co-founder and Chief Distribution Officer at Equine Amnio Solutions. She leads the market introduction of RenoVō and AlphaFlo.

Dr. Jaehyun Kim, PhD, is a bioengineer with 25 years in tissue engineering. He leads placental tissue allograft research at Equus Innovations.

Renovo Equine aims to improve horse health and performance through regenerative therapies.

Renovo Equine offers advice and information about RenoVō and its equine regenerative therapies.

RenoVō equine amniotic tissue allograft to supplement and protect tissues. It's been used in over 20,000 horses as a superior alternative to other modalities.

Equine Amnio Solutions, LLC's privacy policy explains what information the website collects about users and their site use, how it is collected, used, shared, and protected, and what choices users have.

Equine Amnio Solutions, LLC and Affiliates (Collectively, "EAS") Terms and Conditions ("Terms and Conditions")